Disposition of 1724 shares by Graham Reeve of US Physicalrapy at 105.46 subject to Rule 16b-3
USPH Stock | USD 88.18 0.30 0.34% |
Under 53% of US Physicalrapy's investor base is interested to short. The analysis of overall sentiment of trading US Physicalrapy stock suggests that many investors are impartial at this time. US Physicalrapy's investing sentiment shows overall attitude of investors towards US Physicalrapy.
USPH |
Filed transaction by US Physicalrapy Officer: Coo. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
US Physicalrapy Fundamental Analysis
We analyze US Physicalrapy's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of US Physicalrapy using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of US Physicalrapy based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
US Physicalrapy is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
US Physicalrapy Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with US Physicalrapy stock to make a market-neutral strategy. Peer analysis of US Physicalrapy could also be used in its relative valuation, which is a method of valuing US Physicalrapy by comparing valuation metrics with similar companies.
Peers
US Physicalrapy Related Equities
AGL | Agilon Health | 8.85 | ||||
ACHC | Acadia Healthcare | 8.71 | ||||
HCSG | Healthcare Services | 2.62 | ||||
DVA | DaVita HealthCare | 2.00 | ||||
EHAB | Enhabit | 1.55 | ||||
INNV | InnovAge Holding | 1.02 | ||||
PNTG | Pennant | 0.30 | ||||
ADUS | Addus HomeCare | 0.27 | ||||
ENSG | Ensign | 0.28 | ||||
HCA | HCA Holdings | 0.35 | ||||
UHS | Universal Health | 0.43 | ||||
EHC | Encompass Health | 0.73 | ||||
SGRY | Surgery Partners | 0.99 | ||||
THC | Tenet Healthcare | 2.05 | ||||
SEM | Select Medical | 2.08 |
Complementary Tools for USPH Stock analysis
When running US Physicalrapy's price analysis, check to measure US Physicalrapy's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy US Physicalrapy is operating at the current time. Most of US Physicalrapy's value examination focuses on studying past and present price action to predict the probability of US Physicalrapy's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move US Physicalrapy's price. Additionally, you may evaluate how the addition of US Physicalrapy to your portfolios can decrease your overall portfolio volatility.
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation |